BDBM285517 5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide (racemate)::US10077265, Example 4::US10077265, Example 5
SMILES: COCCC(C(=O)Nc1ccn2ncc(C(N)=O)c2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C#N
InChI Key: InChIKey=OCRCHYZWRKVQCQ-UHFFFAOYSA-N
Data: 4 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coagulation factor XI (Homo sapiens (Human)) | BDBM285517 (5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.4 | 25 |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a... | US Patent US10077265 (2018) BindingDB Entry DOI: 10.7270/Q2XS5XFT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM285517 (5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.800 | n/a | n/a | n/a | n/a | 7.4 | 25 |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac... | US Patent US10077265 (2018) BindingDB Entry DOI: 10.7270/Q2XS5XFT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM285517 (5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.70 | n/a | n/a | n/a | n/a | 7.4 | 25 |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac... | US Patent US10077265 (2018) BindingDB Entry DOI: 10.7270/Q2XS5XFT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Coagulation factor XI (Homo sapiens (Human)) | BDBM285517 (5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.40 | n/a | n/a | n/a | n/a | 7.4 | 25 |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a... | US Patent US10077265 (2018) BindingDB Entry DOI: 10.7270/Q2XS5XFT | |||||||||||
More data for this Ligand-Target Pair |